MOUNJARO KWIKPEN 5/MG/0.6/ML 1/PENFILL @

Indications

Approved Uses

Type 2 diabetes mellitus: as an adjunct to diet and exercise to improve glycemic control in adults.

Off-Label Uses

Off-label (not approved for Mounjaro): chronic weight management (this indication is approved for tirzepatide under a different brand in some jurisdictions), and investigational/off-label metabolic uses such as NASH and PCOS-related metabolic dysfunction.

Dosage & Administration

Dosing by Condition

Type 2 diabetes mellitus (adults): 2.5 mg SC once weekly for 4 weeks (initiation), then 5 mg once weekly; if additional glycemic control is needed, increase by 2.5 mg every ≥4 weeks to 7.5 mg, 10 mg, 12.5 mg, or 15 mg; maximum 15 mg once weekly.

Initial Dose

2.5 mg subcutaneously once weekly for 4 weeks (this is a non-therapeutic dose for tolerability). [3, 15, 23]

Maintenance Dose

5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg subcutaneously once weekly. [12, 16]

Maximum Dose

15 mg subcutaneously once weekly.

Children's Dosage

Approved for pediatric patients 10 years and older; maximum 10 mg SC once weekly.

Dose Adjustment Notes

Titrate in 2.5 mg increments no more frequently than every 4 weeks based on tolerability and glycemic need; if used with insulin or an insulin secretagogue (e.g., sulfonylurea), consider dose reduction of those agents to reduce hypoglycemia risk. No dosage adjustment is generally required for renal or hepatic impairment, but monitor renal function if severe GI reactions occur.

How to Take

Administer tirzepatide subcutaneously once weekly in the abdomen, thigh, or upper arm; rotate injection sites. May be given any time of day, with or without meals. Inspect solution (clear, colorless to slightly yellow) and do not use if particulate/discolored. Do not share the pen. Do not administer two doses within 3 days (72 hours).

How to Prepare

Ready-to-use pre-filled pen (no reconstitution); visually inspect solution (clear, colorless to slightly yellow) and do not use if discolored/particulate; attach a new needle for each injection.

Side Effects

Common Side Effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.

Safety & Warnings

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), known serious hypersensitivity to tirzepatide or any of its components. [2, 6, 10]

Warnings & Precautions

Warnings/precautions: thyroid C-cell tumor risk and avoid in MTC/MEN2; pancreatitis monitoring; hypoglycemia risk with insulin/secretagogues; dehydration/AKI risk from GI effects; consider gallbladder disease risk; monitor for hypersensitivity; monitor diabetic retinopathy in at-risk patients; not for type 1 diabetes or DKA.

Age Restriction

Approved for adults and pediatric patients 10 years of age and older; maximum 10 mg weekly in pediatrics.

Drug Interactions

Drug Interactions

Key interactions: (1) insulin/insulin secretagogues (e.g., sulfonylureas, glinides) ↑ hypoglycemia risk-consider dose reduction; (2) oral drugs may have delayed absorption due to slowed gastric emptying; (3) oral hormonal contraceptives-use barrier/backup contraception for 4 weeks after initiation and after each dose escalation.

Interaction Severity

MAJOR/clinically significant: insulin and insulin secretagogues (e.g., sulfonylureas; also glinides) due to increased hypoglycemia risk-consider dose reduction and monitor glucose. MODERATE: oral drugs with narrow therapeutic index or where exposure changes matter (e.g., oral contraceptives-reduced exposure after initiation/dose escalation; warfarin-monitor INR) due to delayed gastric emptying. AVOID/NOT RECOMMENDED: concomitant GLP-1 receptor agonists (additive effects, no added benefit).

Food Interaction

No food restriction: may be administered with or without meals.

Special Populations

Pregnancy

Not recommended (animal data show adverse fetal effects; potential risks to fetus).

Breastfeeding

Not recommended (present in rat milk; unknown if in human milk; consider benefits/risks).

Children

Approved for pediatric patients 10 years and older; maximum 10 mg SC once weekly.

Kidney Impairment

No dose adjustment required for any degree of renal impairment, including end-stage renal disease; monitor renal function if severe GI reactions/dehydration occur.

Liver Impairment

No dose adjustment required in hepatic impairment (mild to severe).

Storage & Patient Advice

Preparation Instructions

Ready-to-use pre-filled pen (no reconstitution); visually inspect solution (clear, colorless to slightly yellow) and do not use if discolored/particulate; attach a new needle for each injection.

Missed Dose

If a dose is missed, administer as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and take the next dose on the regularly scheduled day. Do not take two doses within 3 days (72 hours) of each other.

Patient Counseling

Inject once weekly on the same day each week (time of day flexible), with or without food; rotate sites (abdomen, thigh, upper arm) and use proper technique. If missed, take within 96 hours or skip; do not take two doses within 72 hours. Expect GI effects (nausea/diarrhea/vomiting/constipation) especially after starting or dose increases; use smaller meals and maintain hydration. If using insulin/secretagogues, review hypoglycemia symptoms and management. Seek urgent care for severe abdominal pain (pancreatitis) or gallbladder symptoms. Discuss boxed warning/contraindication regarding personal/family history of medullary thyroid carcinoma or MEN2 and report neck mass/hoarseness/dysphagia. Oral contraceptives: use a barrier method for 4 weeks after initiation and after each dose escalation. Do not share the pen.

Monitoring Requirements

Monitor glycemic control (SMBG as appropriate and HbA1c periodically). Monitor for hypoglycemia when used with insulin/secretagogues. Monitor for pancreatitis symptoms and gallbladder disease. Monitor renal function in patients with severe GI adverse reactions (risk of dehydration/AKI). Monitor for thyroid C-cell tumor risk symptoms (neck mass/hoarseness/dysphagia) per boxed warning precautions.

Pharmacology

Mechanism of Action

A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that increases glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying to improve glycemic control. [7, 21, 28]

Product Information

Available Dosage Forms

Solution for injection in a pre-filled pen for subcutaneous use (KwikPen).

Composition per Dose

Each 0.5 mL dose (single-dose pen): 5 mg tirzepatide; for KwikPen 5 mg/0.6 mL dose: 5 mg tirzepatide from 20 mg/2.4 mL; excipients: sodium phosphate dibasic heptahydrate, sodium chloride, L-arginine hydrochloride, polysorbate 80, water for injections.

Generic Availability

No

OTC Alternatives

No OTC alternative.

Diabetes Type

Type 2

Insulin Type

Not an insulin

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.